Ragna Berthelsen

Dr. Ragna Berthelsen

Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
RBRagna Berthelsen
Ragna Berthelsen
MKMette Klitgaard
Mette Klitgaard
TRThomas Rades
Thomas Rades
AMAnette Mullertz
Anette Mullertz

6 March 2015 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
RBRagna Berthelsen
Ragna Berthelsen
RHRené Holm
René Holm
JJJette Jacobsen
Jette Jacobsen
JKJakob Kristensen
Jakob Kristensen
BABertil Abrahamsson
Bertil Abrahamsson
AMAnette Mullertz
Anette Mullertz

28 October 2016 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
DKDanna Kamstrup
Danna Kamstrup
RBRagna Berthelsen
Ragna Berthelsen
PSPhilip Jonas Sassene
Philip Jonas Sassene
ASArzu Selen
Arzu Selen
AMAnette Mullertz
Anette Mullertz

2 April 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MKMette Klitgaard
Mette Klitgaard
AMAnette Mullertz
Anette Mullertz
RBRagna Berthelsen
Ragna Berthelsen
The aim of this study was to design an in vitro lipolysis-permeation method to estimate drug absorption following the oral administration of self-nanoemulsifying drug delivery systems (SNEDDSs). The method was evaluated by testing five oral formulations containing cinnarizine (four SNEDDSs and one aqueous suspension) from a previously published pharmacokinetic study in rats. In that study, the pharmacokinetic profiles of the five formulations did not correlate with the drug solubilization profiles obtained during in vitro intestinal lipolysis. Using the designed lipolysis-permeation method, in vitro lipolysis of the five formulations was followed by in vitro drug permeation in Franz diffusion cells equipped with PermeaPad® barriers. A linear in vivo–in vitro correlation was obtained when comparing the area under the in vitro drug permeation–time curve (AUC0–3h), to the AUC0–3h of the plasma concentration–time profile obtained from the in vivo study. Based on these results, the evaluated lipolysis-permeation method was found to be a promising tool for estimating the in vivo performance of SNEDDSs, but more studies are needed to evaluate the method further.

1 April 2020 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
NHNele-Johanna Hempel
Nele-Johanna Hempel
MKMatthias M. Knopp
Matthias M. Knopp
RBRagna Berthelsen
Ragna Berthelsen
Axel ZeitlerAxel Zeitler
Axel Zeitler
Korbinian LöbmannKorbinian Löbmann
Korbinian Löbmann

1 October 2014 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
RBRagna Berthelsen
Ragna Berthelsen
ESErik Sjögren
Erik Sjögren
JJJette Jacobsen
Jette Jacobsen
JKJakob Kristensen
Jakob Kristensen
RHRené Holm
René Holm
AMAnette Mullertz
Anette Mullertz